William Blair Has Pessimistic Outlook of TARS Q2 Earnings
| TARS Stock | USD 41.15 0.76 1.81% |
Slightly above 62% of Tarsus Pharmaceuticals' investor base is looking to short. The analysis of overall sentiment of trading Tarsus Pharmaceuticals stock suggests that many investors are alarmed at this time. Tarsus Pharmaceuticals' investing sentiment can be driven by a variety of factors including economic data, Tarsus Pharmaceuticals' earnings reports, geopolitical events, and overall market trends.
Tarsus Pharmaceuticals, Inc. Equities researchers at William Blair cut their Q2 2025 EPS estimates for shares of Tarsus Pharmaceuticals in a report released on Monday, July 14th. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings per share of for the quarter, down from their
Read at thelincolnianonline.com
 |
Tarsus Pharmaceuticals Fundamental Analysis
We analyze Tarsus Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Tarsus Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Tarsus Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Tarsus Pharmaceuticals is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Tarsus Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Tarsus Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Tarsus Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Tarsus Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Tarsus Pharmaceuticals Related Equities
| FDMT | 4D Molecular | 15.46 | ||||
| PHAT | Phathom Pharmaceuticals | 3.47 | ||||
| IVA | Inventiva | 2.80 | ||||
| EWTX | Edgewise Therapeutics | 0.96 | ||||
| VIGL | Vigil Neuroscience | 0.12 | ||||
| VRCA | Verrica Pharmaceuticals | 1.24 | ||||
| INBX | Inhibrx Biosciences, | 3.94 | ||||
| PRAX | Praxis Precision | 6.46 |
Additional Tools for Tarsus Stock Analysis
When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.